Raymond Hurst work email
- Valid
- Valid
Raymond Hurst personal email
25 years of experience advancing CNS drug discovery programs from concept to early clinical development || Expertise building pharmacological relationships that bridge molecular target to systems and behavioral effects to biomarkers that translate to clinical endpoints || Significantly influenced the advancement of multiple compounds to clinical testing || Supported regulatory submissions, late-stage development and commercial programs, nonclinical and clinical safety assessments, and in- and out-licensing opportunities
-
Svp, Head Of DiscoveryArkuda Therapeutics Jan 2023 - PresentWatertown, Massachusetts, Us -
Vice President, PharmacologyArkuda Therapeutics Feb 2020 - Jan 2023Watertown, Massachusetts, Us
-
Director, Biology & PharmacologyConcert Pharmaceuticals, Inc. Mar 2018 - 2020
-
Neuropharmacology And Translational ScienceConsultant Nov 2017 - Mar 2018
-
Senior Director, PharmacologyQuartet Medicine Aug 2016 - Oct 2017Cambridge, Massachusetts, UsUtilized external resources to conduct nonclinical in vivo and in vitro pharmacology studies to support delivery of a Development Candidate for chronic painDeveloped PKPD models of peripheral and central actions of sepiapterin reductase (SPR) inhibitors to define criteria for a Second Generation SPR inhibitorContributed to design of non-interventional and Phase 1 biomarker studies Prepared nonclinical pharmacology sections for regulatory submission -
Director And Head Of PharmacologyForum Pharmaceuticals Jan 2014 - Jun 2016UsDirected a pharmacology group responsible for supporting the Research portfolio with behavior, neurophysiology and receptor pharmacology Co-led a next generation α7 nicotinic receptor agonist team that delivered a preclinical candidate achieving key efficacy, safety, PK and biomarker goalsDesigned and oversaw pharmacology studies conducted in-house and at contract research organizationsServed on a cross functional team to define and minimize risk of GI safety events that were observed in Phase 3 clinical studies, and specifically delivered a comprehensive assessment of the relationship between receptor engagement and adverse events for marked drugs sharing overlapping pharmacologyReviewer for Nonclinical Pharmacology section of a NDA Provided scientific support for licensing and partnership discussions -
Principal ScientistAmgen Dec 2012 - Jan 2014Thousand Oaks, Ca, UsOversight of electrophysiology for lead program targeting a voltage-gated sodium channel for neuropathic painDelivered high-throughput electrophysiology screening data for SAR campaign Identified discrete types of inhibitors based on biophysical characteristics measured with in vitro electrophysiology methodsDirected key proof of principal studies utilizing an ex vivo skin-saphenous nerve preparation -
Senior Principal Scientist & Discovery Operations LeadPfizer Sep 2003 - Dec 2012New York, New York, UsDesigned a successful high throughput screening approach utilizing embryonic stem cells to identify novel modulators of native AMPA-type glutamate receptors Initiated a drug discovery program for AMPA positive modulators that led to clinical evaluation of PF-04958242 Designed and implemented nonclinical pharmacology studies that supported dose selection for Phase 2 clinical studies with the α4β2 nicotinic acetylcholine receptor partial agonist CP-601927Led drug discovery projects for multiple preclinical programs targeting ligand gated ion channel and G-protein coupled receptor targetsCore member of drug discovery team that advanced the α7 nicotinic receptor agonist CP-810123 to clinical testingResponsible for nonclinical Pharmacology section of the IND for CP-810123 Provided support for marketed drug (Chantix®) through directed research and publications related to mechanism of action and safety -
Principal ScientistPfizer Nov 1998 - Sep 2003New York, New York, UsDevelop in vitro and ex vivo electrophysiology strategy for α7 nicotinic receptor agonist program that advanced PHA-568487 and PHA-543613 to clinical testing Led the α7 nicotinic receptor positive allosteric modulator program that discovered and described PNU-120596, a widely used research toolDesigned strategy and oversaw studies to assess risk of QTc prolongation for nonclinical and clinical programs (sumanirole, sonepiprazole)
-
Postdoctoral FellowUcla, Mental Retardation Research Center May 1997 - Nov 1998Supervisor: Prof. Michael S. LevineDevelopment and modulation of synaptic transmission in the basal ganglia Neuronal pathophysiology associated human epilepsy Neuronal pathophysiology associated with mouse model of Huntington’s disease
-
Postdoctoral FellowUcla, Dept. Of Anesthesiology Mar 1994 - Apr 1997Supervisor: Prof. Enrico StefaniCharacterization and regulation of ionic currents mediated by human transient receptor potential channelsBiophysical and structural properties of voltage-gated potassium channels
Raymond Hurst Skills
Raymond Hurst Education Details
-
Oregon Health & Science UniversityCell Biology And Anatomy -
Texas A&M UniversityMicrobiology
Frequently Asked Questions about Raymond Hurst
What company does Raymond Hurst work for?
Raymond Hurst works for Arkuda Therapeutics
What is Raymond Hurst's role at the current company?
Raymond Hurst's current role is SVP - Discovery.
What is Raymond Hurst's email address?
Raymond Hurst's email address is ra****@****bal.net
What schools did Raymond Hurst attend?
Raymond Hurst attended Oregon Health & Science University, Texas A&m University.
What skills is Raymond Hurst known for?
Raymond Hurst has skills like In Vitro, Pharmacology, Neuroscience, Drug Discovery, Assay Development, Cell, Electrophysiology, Biotechnology, Life Sciences, Drug Development, Ion Channels, In Vivo.
Free Chrome Extension
Find emails, phones & company data instantly
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial